Effects of dalcetrapib in patients with a recent acute coronary syndrome

Gregory G Schwartz, Anders G Olsson, Markus Abt, Christie M Ballantyne, Philip J Barter, Jochen Brumm, Bernard R Chaitman, Ingar M Holme, David Kallend, Lawrence A Leiter, Eran Leitersdorf, John J V McMurray, Hardi Mundl, Stephen J Nicholls, Prediman K Shah, Jean-Claude Tardif, R Scott Wright, dal-OUTCOMES Investigators

1725 Citationer (Scopus)

Abstract

In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes.
OriginalsprogEngelsk
TidsskriftThe New England journal of medicine
Vol/bind367
Udgave nummer22
Sider (fra-til)2089-99
Antal sider11
ISSN0028-4793
DOI
StatusUdgivet - 29 nov. 2012

Fingeraftryk

Dyk ned i forskningsemnerne om 'Effects of dalcetrapib in patients with a recent acute coronary syndrome'. Sammen danner de et unikt fingeraftryk.

Citationsformater